Medicare Enrolled

Dr. Nicholas Short, MD

Hematology & Oncology · Houston, TX
Practice pattern: Clinical Cardiology— Primarily office-based clinical cardiology
Consulting-driven
1515 HOLCOMBE BLVD, Houston, TX 77030
7137926161
In practice since 2011 (14 years)
NPI: 1396039178 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Short from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Short? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Short

Dr. Nicholas Short is a hematology & oncology in Houston, TX, with 14 years in practice. Based on federal Medicare data, Dr. Short performed 854 Medicare services across 277 unique beneficiaries.

Between the years covered by Open Payments, Dr. Short received a total of $153,510 from 16 pharmaceutical and/or device companies across 86 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. The majority of payments are for consulting, which typically reflects recognized clinical expertise sought by manufacturers. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Short is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 14 years in practice▲ 854 Medicare services$ $153,510 industry payments

Medicare Practice Summary

Medicare Utilization ↗
854
Medicare services
Bottom 45% in TX for hematology & oncology
277
Unique beneficiaries
$104
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~61 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

ProcedureVolumeAvg. paidAvg. submitted
Hospital follow-up visit, high complexity405$96$285
Office visit, established patient, complex (40-54 min)324$109$533
Initial hospital admission, high complexity58$139$600
Hospital discharge management, 30+ min53$87$327
New patient office visit, complex (60-74 min)14$146$571
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.

Industry Payment Transparency

Open Payments through 2024 ↗
$153,510
Total received (2018-2024)
Avg $21,930/year across 7 years
Top 4% in TX for hematology & oncology
16
Companies
86
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$77,782 (50.7%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$74,798 (48.7%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$930 (0.6%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$47,870
2023
$47,971
2022
$24,222
2021
$11,687
2020
$3,500
2019
$11,178
2018
$7,082

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
Adaptive Biotechnologies Corporation
$62,045
Amgen Inc.
$46,830
GENZYME CORPORATION
$12,723
PFIZER INC.
$7,014
GlaxoSmithKline, LLC.
$6,500
Novartis Pharmaceuticals Corporation
$5,240
Takeda Pharmaceuticals U.S.A., Inc.
$3,805
JAZZ PHARMACEUTICALS INC.
$3,200
AstraZeneca Pharmaceuticals LP
$3,104
Astellas Pharma Global Development
$2,337
Cepheid
$417
Astellas Pharma US Inc
$147
Celgene Corporation
$66
Gilead Sciences, Inc.
$42
ABBVIE INC.
$27
MorphoSys, US Inc.
$15
Top 3 companies account for 79.2% of total payments
Associated products mentioned in payments ›
BESPONSA · BOSULIF · Blincyto · ELITEK · EPKINLY · ICLUSIG · LUMOXITI · MONJUVI · REBLOZYL · RYLAZE · Xospata · clonoSEQ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

The majority of payments (51%) are consulting fees, which typically reflect recognized clinical expertise sought by manufacturers. Total industry engagement is in the top 4% for hematology & oncology in TX.

Equivalent to $17,975 per 100 Medicare services performed
Looking for a hematology & oncology in Houston?
Compare hematology & oncologys in the Houston area by procedure volume, costs, and industry payment transparency.
Browse hematology & oncologys nearby

Geographic Context

Hematology & Oncologys within 10 mi
202
Per 100K population
4.2
County median income
$73,104
Nearest hospital
MEMORIAL HERMANN - TEXAS MEDICAL CENTER
0.0 mi

Data Sources

Provider Registry NPPESWeekly updates
Medicare Enrollment PECOSMonthly updates
Practice Data Medicare Util.Annual (CY lag)
Industry Payments Open PaymentsCY 2024
Disciplinary History— Not publicN/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →

Summary

Dr. Short is a clinical cardiology specialist, with moderate Medicare volume, and high industry engagement (consulting-driven, top 4%).

This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →

Frequently Asked Questions

Is Dr. Short experienced with hospital follow-up visit, high complexity?
Based on Medicare claims data, Dr. Short performed 405 hospital follow-up visit, high complexity services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Short receive payments from pharmaceutical companies?
Yes. Dr. Short received a total of $153,510 from 16 companies across 86 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Short's costs compare to other hematology & oncologys in Houston?
Dr. Short's average Medicare payment per service is $104. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Short) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →